Naᵥ1.8 is a sodium ion channel subtype that in humans is encoded by the SCN10A gene. Naᵥ1.8-containing channels are tetrodotoxin-resistant voltage-gated channels. From Wikipedia
The biotech will shift focus to a Phase 3 study of Journavx in diabetic neuropathy following the failed VX-993 trial.
